This White Paper provides a foundational understanding of insights management, including the definition and value of insights, processes and technologies for insights management, and key challenges in implementation.
Based on discussions between 80 cross-industry Field Medical colleagues from small to large biopharmaceutical and medtech companies, this article highlights key actions for Medical Affairs teams to consider for implementation in their own organizations.
This article outlines the aspects of Medical Affairs strategy and launch excellence specific to supporting the development and launch of treatments targeting rare diseases, providing a roadmap for MA teams and organizations undertaking this planning.
This white paper by the MAPS Executive Consortium synthesizes the views of senior global Medical Affairs leaders to provide a unified vision for the future of Medical Affairs in society, industry, teams and as individuals.
What is Medical Affairs and what does it do in the biopharmaceutical and MedTech industries? Who works in Medical Affairs and what skills do you need to succeed? Find out in this essential guide to understanding, joining and thriving in Medical Affairs.
In this white paper, MedComms, Field Medical and Insights Focus Area Working Groups (FAWGs) demonstrate the value of and elucidate best practices for an insights-driven collaborative approach to creating an iMC S/P.
This white paper provides Medical Affairs professionals with the background and history of Real-World Evidence, and its applications in the biopharma industry to benefit patients.
Digitalization offers Medical Affairs teams the opportunity to rethink strategy and actions across the lifecycle of traditional and nontraditional products.
A guide for Medical Communications cross-functional collaboration to develop an Integrated Medical Communications Strategy and Plan (iMC S/P) which is the roadmap for how a Medical Affairs team communicates its product vision and value proposition to internal and external stakeholders.
There is growing interest globally in using real-world data (RWD) and real-world evidence (RWE) for applications including regulatory decisions, health technology assessment (HTA), pharmacovigilance and more. However, Asia currently lacks a framework to effectively collect and utilize a broad range of RWD/RWE.